Table 2 |
||||
| Prevalence of CKD in high school students of Kinshasa | ||||
| Schwartz | MDRD | CG indexed BSA | CG | |
| mL/min/ 1.73 m2 | mL/min/ 1.73 m2 | mL/min/ 1.73 m2 | mL/min | |
| 1 | 4 (0.8) | 4(0.8) | 2 (0.4) | 2 (0.4) |
| 2 | 0 | 1(0.2) | 3 (0.6) | 3 (0.6) |
| 3 | 4(0.8) | 4(0.8) | 10 (1.9) | 35 (6.7) |
| 4 | 0 | 0 | 0 | 0 |
| 5 | 0 | 0 | 0 | 0 |
| All stage | 8 (1.5) | 9 (1.7) | 15 (2.9) | 40 (7.6) |
Values expressed as numbers and proportions (%) in parentheses.
CKD is defined as either kidney damage (proteinuria ≥ 300 mg/day) and/or kidney function (< 60ml/min/1.73 m2). KDIGO CKD stages are defined as follows: stage 1, proteinuria ≥ 300 mg per day with an eGFR ≥ 90 mL/min/1.73 m2; stage 2, proteinuria ≥ 300 mg/day with an eGFR of 60–89 mL/min/1.73 m2; stage 3, an eGFR of 30–59 mL/min/1.73 m2, stage 4, an eGFR of 15–29 mL/min/1.73 m2 and stage 5, an eGFR < 15 mL/min/1.73 m2.
Bukabau et al. BMC Nephrology 2012 13:24 doi:10.1186/1471-2369-13-24
